**Immunologic Heterogeneity in 2 Cartilage-Hair Hypoplasia Patients With a Distinct Clinical Course**

Gamliel A¹,², Lee YN¹,², Lev A¹,², AbuZaitun O³, Rechavi E¹,², Levy S¹, Simon AJ¹,⁴*, Somech R¹,²*

¹Pediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel Hashomer, Israel
²Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
³Ambulatory Pediatrics, Nablus, Palestinian Authority
⁴Hematology Laboratory, Hemato-Immunology Unit, and Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel
*Both authors jointly supervised this work

**Abstract**

*Introduction:* Cartilage-hair hypoplasia (CHH) syndrome is a rare autosomal recessive syndrome associated with skeletal dysplasia, varying degrees of combined immunodeficiency (CID), short stature, hair hypoplasia, macrocytic anemia, increased risk of malignancies, and Hirschsprung disease.

*Purpose:* To provide clinical and immunological insights obtained from 2 unrelated patients who displayed clinical characteristics of CHH.

*Methods:* Two patients with suspected CHH syndrome due to skeletal dysplasia and immunodeficiency underwent an immunological and genetic work-up using flow cytometry, next-generation sequencing (NGS) of the immune repertoire, and Sanger sequencing to identify the underlying defects.

*Results:* Patient 1 presented with low birth weight and skeletal dysplasia. Newborn screening was suggestive of T-cell immunodeficiency, as T-cell receptor excision circle levels were undetectable. Both the T-cell receptor (TCR) Vβ and TCR-γ (TRG) repertoires were restricted, with evidence of clonal expansion. Genetic analysis identified compound heterozygous RMRP variants inherited from both parents. Patient 2 presented with recurrent lung and gastrointestinal infections, skeletal dysplasia, failure to thrive, and hepatomegaly. The polyclonal pattern of the TCRβ repertoire was normal, with only slight overexpression of TCR-β2 and restricted expression of Vβs. TRG expressed a normal diverse repertoire, similar to that of the healthy control sample. Genetic analysis identified biallelic novel regulatory variants in RMRP. Both parents are carriers of this mutation.

*Conclusion:* Our findings demonstrate how the immunological work-up, supported by genetic findings, can dramatically change treatment and future outcome in patients with the same clinical syndrome.

**Key words:** RMRP. Severe combined immunodeficiency (SCID). Cartilage-Hair Hypoplasia (CHH). NGS. TCR repertoire.

**Resumen**

*Introducción:* El síndrome de hipoplasia de cartílago-cabello (CHH) es un síndrome autosómico recesivo poco frecuente, asociado con displasia esquelética, diversos grados de inmunodeficiencia combinada (CID), baja estatura, hipoplasia del cabello, anemia macrocitica junto a un mayor riesgo desarrollar de tumores malignos y enfermedad de Hirschsprung.

*Propósito:* Proporcionar conocimientos clínicos e inmunológicos obtenidos de dos pacientes, sin relación familiar, que mostraron características clínicas de CHH.

*Métodos:* Dos pacientes con sospecha de síndrome CHH debido a la presencia de displasia esquelética e inmunodeficiencia, se sometieron a un estudio inmunológico y genético mediante citometría de flujo, secuenciación de próxima generación (NGS) del repertorio inmune y secuenciación de Sanger, para identificar los defectos subyacentes.

*Resultados:* Paciente 1: presenta al nacimiento bajo peso y displasia esquelética. El cribado de recién nacidos (NBS, por sus siglas en inglés) sugirió una inmunodeficiencia de células T, ya que los niveles del receptor de células T (TREC, por sus siglas en inglés) eran indetectables. El estudio posterior reveló anemia macrocitica, linfopenia grave e hipogammaglobulinemia. Tanto el repertorio del receptor de células T (TCR) - Vβ como el repertorio del receptor de células T gamma (TRG) estaban restringidos y con evidencia de expansión clonal. El análisis genético identificó variantes heterocigóticas compuestas heredadas de ambos padres en RMRP. Paciente 2: presentaba una clínica de infecciones pulmonares y gastrointestinales recurrentes, displasia esquelética, retraso en el crecimiento y hepatomegalia. El estudio inmunológico, el hemograma completo (CSC) y los análisis de subpoblaciones de linfocitos fueron normales. El repertorio de TCRβ reveló un patrón policlonal normal con solo una ligera sobreexpresión de TCR-BV20 y varias expresiones restringidas de Vβs. TRG expresó un...
Introduction

Cartilage-hair hypoplasia (CHH) syndrome is a rare autosomal recessive syndrome characterized by chondrodysplasia, variable degrees of combined immunodeficiency (CID), short stature, hair hypoplasia, anemia, increased risk of malignancies, and Hirschsprung disease. The syndrome is caused by mutations in RMRP, a gene encoding the untranslated RNA component of mitochondrial RNA processing endoribonuclease. This ribonucleoprotein cleaves mitochondrial RNA at a priming site to form a distinct ribonucleoprotein complex that interacts with the telomerase reverse transcriptase (TERT) catalytic subunit in order to produce double-stranded RNAs that can be processed into small interfering RNA [1]. The prevalence of CHH is exceptionally high among specific populations including the Finnish and the Amish [2], and more than 70 RMRP mutations have been identified to date. Mutations are found mainly in the transcribed region and the promoter region (from the TATA box to the transcription initiation site) of the RMRP gene. The most common mutation is the +70A>G point mutation [3-6]. Overall mortality is high in CHH, mostly from malignancies and lung disease related to immunodeficiency. Median age at death from immunodeficiency-related causes was found to be 40.9 years [7].

Clinical heterogeneity and variable degrees of immunodeficiency have been reported among patients harboring RMRP variants. Abnormalities of cellular immunity can range from severe impairment causing severe combined immunodeficiency (SCID), ie, T- and B-cell deficiency, to near normal with no clinical significance [6,8-10]. In addition, immune dysregulation leading to a wide spectrum of autoimmune manifestations is also frequent in the CHH patient [11]. For some CHH patients who display severe T-cell immunodeficiency, early diagnosis is possible through a newborn screening panel and is clinically important. This may prevent future infections and clinical deterioration, since adequate isolation and treatment can be initiated immediately. Newborn screening for severe T-cell immunodeficiency is widely performed using detection of T-cell receptor excision circles (TRECs) in dried blood spots collected on Guthrie cards. This assay is increasingly used for newborn screening for SCID worldwide, as well as in Israel [12]. Interestingly, the TREC assay can also identify newborns with syndromes (those associated with severe T-cell immunodeficiency), newborns with secondary causes of T-cell immunodeficiency, and newborns with T-cell lymphopenia. Thus, it is possible to identify some, but not all, CHH patients with profound T-cell lymphopenia [13]. Hematopoietic stem cell transplantation (HSCT) has profoundly changed the natural history of severe T-lymphocyte deficiencies by curing many patients with SCID and CID [14]. In contrast to SCID, not all CHH patients should be considered for HSCT. Only those with chronic or recurrent infections in association with autoimmune or bone marrow hypoplasia are good candidates if a well-matched donor is available [15].

In this study, we describe the immune work-up of 2 unrelated patients who presented with clinical findings suggestive of CHH. One was diagnosed through newborn screening for SCID and, interestingly, displayed severe immunodeficiency including an abnormal T-cell receptor repertoire, while the other was diagnosed at the age of 1 year based mainly on skeletal dysplasia and recurrent lung and gastrointestinal infections. We used next-generation sequencing (NGS) to determine the T-cell receptor (TCR) repertoire. In both patients, Sanger sequencing identified distinct mutations in the RMRP gene. This research extends our current understanding of CHH in patients with suspected immunodeficiency and the correlation between their T-cell receptor γ (TRG) repertoire and their diseases.
Methods

Clinical Data

Clinical information was obtained from the patients’ electronic medical records. All procedures were performed in accordance with the ethical standards of the institutional and/or national research committee and with the Declaration of Helsinki and its later amendments or comparable ethical standards.

Immunologic Evaluation

Neutrophil engraftment was confirmed after 3 consecutive days with an absolute count of over $0.5 \times 10^9/L$. Lymphocyte engraftment and chimerism were evaluated mainly by analysis of microsatellite variable numbers of tandem repeats, and fluorescence in situ hybridization studies using Y-specific probes in sex-mismatched couples. Absolute numbers and percentages of lymphocytes were quantified by assessment of cell surface markers using immunofluorescent staining and flow cytometry (Epics V, Beckman Coulter) with antibodies purchased from Beckman Coulter. Serum immunoglobulin concentrations (IgG, IgM, IgA) were measured using standard nephelometry.

Results

Clinical Description

We present 2 unrelated patients who were evaluated for suspected CHH. Patient 1 was born to a healthy nonconsanguineous Ashkenazi-Jewish couple after spontaneous pregnancy. Fetal ultrasound in the third trimester revealed short long bones. The mother gave birth to a girl at 34 weeks of gestation (birth weight of 1800 g and length of 35 cm ([–2 SD]). The postnatal period was uneventful. Newborn screening was suggestive of T-cell immune deficiency, as TREC levels were undetectable. At the fourth week of life, the blood work-up showed severe lymphopenia and anemia (Table).

Patient 2 was brought to our clinic at age 1 year, mainly to evaluate his recurrent infections. He was born to healthy nonconsanguineous Palestinian parents. His birth weight was 3.3 kg. After birth, the patient was noticed to have short limbs. At the second month of life, examination revealed hepatosplenomegaly. The patient later presented with poorness weight gain. At the first year of life, he weighed only 7.6 kg and 4 months later 7.8 kg (−3 SD). Since birth, he had experienced recurrent pneumonia (once a month) and multiple episodes of gastroenteritis, some of which required hospitalization. Initial findings in our hospital were short stature (72 cm, –3 SD), short limbs, skeletal dysplasia, failure to thrive, and hepatomegaly.

Immunological Evaluation

The initial immunologic evaluation for patient 1 at the fourth week of life revealed severe lymphopenia with depleted T and B cells (Table). Lymphocyte proliferation consisted of trimethoprim/sulfamethoxazole for *Pneumocystis jiroveci* (PCP), intravenous immunoglobulin (IVIG) to maintain IgG levels above 6 g/L, acyclovir in the case of donor–recipient serologic cytomegalovirus disparity, and cyclosporine A for graft-versus-host disease (GVHD). Granulocyte colony-stimulating factor was given from the day of transplant until neutrophil counts were $>1.0 \times 10^9/L$ for 3 consecutive days. The HSCT infusion itself originated from bone marrow. Conditioning regimens were based on the European Group for Blood and Marrow Transplantation and European Society for Immunodeficiencies guidelines for HSCT in PID.

Bone Marrow Transplantation

Patients underwent transplantation in house, at our hematology-oncology unit. Standard prophylactic medications consisted of trimethoprim/sulfamethoxazole for *Pneumocystis jiroveci* (PCP), intravenous immunoglobulin (IVIG) to maintain IgG levels above 6 g/L, acyclovir in the case of donor–recipient serologic cytomegalovirus disparity, and cyclosporine A for graft-versus-host disease (GVHD). Granulocyte colony-stimulating factor was given from the day of transplant until neutrophil counts were $>1.0 \times 10^9/L$ for 3 consecutive days. The HSCT infusion itself originated from bone marrow. Conditioning regimens were based on the European Group for Blood and Marrow Transplantation and European Society for Immunodeficiencies guidelines for HSCT in PID.

Engraftment and Immunologic Assessment

Neutrophil engraftment was confirmed after 3 consecutive days with an absolute count of over $0.5 \times 10^9/L$. Lymphocyte engraftment and chimerism were evaluated mainly by analysis of microsatellite variable numbers of tandem repeats, and fluorescence in situ hybridization studies using Y-specific probes in sex-mismatched couples. Absolute numbers and percentages of lymphocytes were quantified by assessment of cell surface markers using immunofluorescent staining and flow cytometry (Epics V, Beckman Coulter) with antibodies purchased from Beckman Coulter. Serum immunoglobulin concentrations (IgG, IgM, IgA) were measured using standard nephelometry.

Results

Clinical Description

We present 2 unrelated patients who were evaluated for suspected CHH. Patient 1 was born to a healthy nonconsanguineous Ashkenazi-Jewish couple after spontaneous pregnancy. Fetal ultrasound in the third trimester revealed short long bones. The mother gave birth to a girl at 34 weeks of gestation (birth weight of 1800 g and length of 35 cm ([–2 SD]). The postnatal period was uneventful. Newborn screening was suggestive of T-cell immune deficiency, as TREC levels were undetectable. At the fourth week of life, the blood work-up showed severe lymphopenia and anemia (Table).

Patient 2 was brought to our clinic at age 1 year, mainly to evaluate his recurrent infections. He was born to healthy nonconsanguineous Palestinian parents. His birth weight was 3.3 kg. After birth, the patient was noticed to have short limbs. At the second month of life, examination revealed hepatosplenomegaly. The patient later presented with poor weight gain. At the first year of life, he weighed only 7.6 kg and 4 months later 7.8 kg (−3 SD). Since birth, he had experienced recurrent pneumonia (once a month) and multiple episodes of gastroenteritis, some of which required hospitalization. Initial findings in our hospital were short stature (72 cm, –3 SD), short limbs, skeletal dysplasia, failure to thrive, and hepatomegaly.

Immunological Evaluation

The initial immunologic evaluation for patient 1 at the fourth week of life revealed severe lymphopenia with depleted T and B cells (Table). Lymphocyte proliferation consisted of trimethoprim/sulfamethoxazole for *Pneumocystis jiroveci* (PCP), intravenous immunoglobulin (IVIG) to maintain IgG levels above 6 g/L, acyclovir in the case of donor–recipient serologic cytomegalovirus disparity, and cyclosporine A for graft-versus-host disease (GVHD). Granulocyte colony-stimulating factor was given from the day of transplant until neutrophil counts were $>1.0 \times 10^9/L$ for 3 consecutive days. The HSCT infusion itself originated from bone marrow. Conditioning regimens were based on the European Group for Blood and Marrow Transplantation and European Society for Immunodeficiencies guidelines for HSCT in PID.

Engraftment and Immunologic Assessment

Neutrophil engraftment was confirmed after 3 consecutive days with an absolute count of over $0.5 \times 10^9/L$. Lymphocyte engraftment and chimerism were evaluated mainly by analysis of microsatellite variable numbers of tandem repeats, and fluorescence in situ hybridization studies using Y-specific probes in sex-mismatched couples. Absolute numbers and percentages of lymphocytes were quantified by assessment of cell surface markers using immunofluorescent staining and flow cytometry (Epics V, Beckman Coulter) with antibodies purchased from Beckman Coulter. Serum immunoglobulin concentrations (IgG, IgM, IgA) were measured using standard nephelometry.
Immunological Analysis of CHF Patients

The γ chain (TRG) repertoire was performed on PBMCs from both patients and a healthy age-matched control. Of the 4 chains of TCR (α, β, γ, δ), the TRG repertoire was specifically selected for sequencing because it is rearranged earlier in the development of T cells and is often used for sensitive and comprehensive detection of clonal expansions [4,5,17].

As shown in Figure 2A, the treemaps for the TRG repertoire determine that patient 1 expressed a restricted diverse repertoire with evidence of clonal expansion consistent with abnormal T-cell selection within the thymus. Patient 2, on the other hand, expressed a normal diverse repertoire, similar to that of the healthy control. We used the Shannon H and Simpson D indices [4] to measure the diversity of the repertoires. These was markedly reduced following stimulation with PHA. In order to evaluate thymus activity and naïve T-cell production, TRECs in peripheral blood were quantified. The TREC level was remarkably low (Table). Hypogammaglobulinemia was detected based on the absence of IgA and low levels of IgM. IgG levels were borderline, as expected in the postnatal period. At the age of 3 months, IgG levels were 342 mg/dL (normal range, 470-1230 mg/dL), and monthly replacement therapy was started with IVIG.

The TCR-Vβ repertoire was assessed using the traditional TCR-Vβ assay with flow cytometry. Patient 1 had a monoclonal pattern with overexpression of TCR-Vβ12, compared with healthy controls (Figure 1). Taken together, the laboratory results were suggestive of SCID. The patient was also assessed for cell chimerism upon diagnosis owing to suspected transplacentally acquired maternal T cells (a pathognomonic feature of SCID) and showed no chimerism after birth. Patient 2’s immunologic evaluation was performed at the age of 1 year. Findings for the complete blood count and lymphocyte subpopulations were normal (Table). The TREC level was low (Table). The TCR-Vβ repertoire revealed a normal polyclonal pattern with only slight overexpression of TCR-Vβ20 and very restricted TCR-Vβ expression, compared with healthy controls (Figure 1).

**TRG Repertoire Analyses**

In order to further characterize the TCR repertoire, high-throughput immune sequencing of the T-cell receptor γ chain (TRG) repertoire was performed on PBMCs from both patients and a healthy age-matched control. Of the 4 chains of TCR (α, β, γ, δ), the TRG repertoire was specifically selected for sequencing because it is rearranged earlier in the development of T cells and is often used for sensitive and comprehensive detection of clonal expansions [4,5,17].

As shown in Figure 2A, the treemaps for the TRG repertoire determine that patient 1 expressed a restricted diverse repertoire with evidence of clonal expansion consistent with abnormal T-cell selection within the thymus. Patient 2, on the other hand, expressed a normal diverse repertoire, similar to that of the healthy control. We used the Shannon H and Simpson D indices [4] to measure the diversity of the repertoires. These

---

**Table. Immune Profile at Presentation.**

<table>
<thead>
<tr>
<th></th>
<th>P1 (4 wk)</th>
<th>P2 (16 mo)</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphocytes/mm³</td>
<td>870</td>
<td>2002</td>
<td>2900-11 400/1400-12 000</td>
</tr>
<tr>
<td>Lymphocyte subsets, cells/mm³</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T cells</td>
<td>87</td>
<td>1211</td>
<td>1900-8400/700-8800</td>
</tr>
<tr>
<td>CD4</td>
<td>35</td>
<td>480</td>
<td>1500-6000/400-7200</td>
</tr>
<tr>
<td>CD8</td>
<td>139</td>
<td>360</td>
<td>300-2700/200-2800</td>
</tr>
<tr>
<td>B cells</td>
<td>165</td>
<td>320</td>
<td>180-3500/160-3700</td>
</tr>
<tr>
<td>NK</td>
<td>55</td>
<td>29</td>
<td>6-30</td>
</tr>
<tr>
<td>TREC</td>
<td>12</td>
<td>&gt;400</td>
<td></td>
</tr>
<tr>
<td>Immunoglobulins, mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG</td>
<td>496</td>
<td>590-1430</td>
<td></td>
</tr>
<tr>
<td>IgA</td>
<td>Undetectable</td>
<td>38-222</td>
<td></td>
</tr>
<tr>
<td>IgM</td>
<td>24</td>
<td>56-208</td>
<td></td>
</tr>
<tr>
<td>Proliferation capacitya</td>
<td></td>
<td>Healthy donor</td>
<td></td>
</tr>
<tr>
<td>No mitogen</td>
<td>1381</td>
<td>1097</td>
<td></td>
</tr>
<tr>
<td>PHA 6, µg/ml</td>
<td>2327</td>
<td>103 158</td>
<td></td>
</tr>
<tr>
<td>PHA 25, µg/ml</td>
<td>3822</td>
<td>13 5014</td>
<td></td>
</tr>
<tr>
<td>Anti-CD3 antibody</td>
<td>2379</td>
<td>36 154</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: PHA, phytohemagglutinin; TREC, T-cell receptor excision circle.

*Counts per minute of H3-thymidine uptake in response to mitogens.
are commonly used in ecology [18-20]. The diversity indices take into account the unique and total sequences and the evenness of the clonal size. Thus, the Shannon H index reflects the overall diversity of the repertoire, whereas the Simpson D index focuses on how unevenly the clones are distributed in a given repertoire due to the presence of clonal expansions, as previously shown [19,20]. The Shannon H diversity index for patient 1 repertoires was relatively low compared with patient 2 and the controls (Figure 2C). Calculation of the Simpson D index showed unevenness in the TRG repertoire for patient 1 compared with patient 2 and the controls (Figure 2B). Thus, in accordance with the treemaps, the diversity indices showed that patient 1 but not patient 2 had a restricted and clonally expanded TRG repertoire compared with the controls. Nonproductive sequences of the TRG were also analyzed, although the results did not differ from those of the productive sequences (Figure S1).

**Genetic Analyses**

Sanger sequencing revealed 3 distinct mutations in the *RMRP* gene of both patients. Two of the mutations are known [1,21] and 1 is novel. Familial segregations were elucidated (Figures 3 and 4). In the case of patient 1, biallelic compound heterozygous known mutations were found (Figure 3). The first mutation, which was maternally inherited, is a small 17-nucleotide duplication, 4 nucleotides upstream from the transcription initiation site (TIS) (1). The second mutation, which was paternally inherited, is a regulatory mutation of C to T at +238 relative to the TIS (20). In patient 2, a homozygous novel regulatory mutation was found at +222 relative to the TIS. Both parents are carriers of this mutation (Figure 4).

**HSCT for Patient 1**

Patient 1 was 10 months old when he underwent transplantation. Conditioning was with treosulfan/fludarabine. A brother was found to be a matched related donor. As described, GVHD prophylaxis, when used, was based mainly on cyclosporine A. Mycophenolate mofetil and corticosteroids were added when GVHD was suspected or diagnosed. Acute and chronic GVHD appeared only in conditioned patients, all of whom received adequate prophylaxis.
**Immune Reconstitution**

Neutrophil engraftment was confirmed on day +12 after HSCT, lymphopenia (defined as an absolute lymphocyte count <2500) recovered 5 months after HSCT and remained stable until present. T-cell deficiency (CD3 <1000) recovered 6 months after HSCT, and immunoglobulin levels recovered 3 months after HSCT.

Normal TREC levels (>400 copies) were detected 6 months after HSCT.

Chimerism based on FISH studies using Y-specific probes in sex-mismatched couples was 100% 3 months after HSCT and remained stable at 60% 1 year after HSCT.

**Discussion**

CHH is a well-known syndromic PID with a wide spectrum of clinical presentations, specifically regarding the immune system. Patients can be diagnosed immediately after birth through newborn screening for SCID or later in life, based on clinical suspicion.

In this report, we describe 2 patients diagnosed with CHH based on clinical and molecular findings. Patient 1 was identified through the Israeli newborn screening program. CHH patients with absent TREC tend to have a greater immunodeficiency, thus making the diagnostic process much simpler. CHH patients with positive results through the newborn screening program are likely to follow a different route of treatment [13,22]. Recent studies summarizing the latest results of the newborn SCID screening programs revealed several outcomes. Besides the diagnosis of typical SCID, syndromes such as DiGeorge syndrome, trisomy 21, trisomy 18, and CHARGE syndrome accompanied by severe lymphopenia were also identified using the TREC test [23-25]. In addition, these studies detected 2 CHH patients. The first CHH patient, who was diagnosed with SCID and clinical manifestations of skeletal dysplasia and Hirschsprung disease, died at the age of 1 month. Her RMRP mutation was discovered postmortem. The second patient was initially diagnosed with leaky SCID and was characterized by intrauterine growth restriction and short limbs [23,24]. Scott et al [22] described 8 Amish CHH patients with abnormal TREC levels who tested positive in newborn screening. Four patients had absent TREC and tended to have a greater degree of immunodeficiency. Patient 2 had also presented with low TREC levels. Unfortunately, there is no newborn screening TREC program in the Palestinian territories, and the evaluation was based on clinical suspicion.

As often seen in patients with CHH who present with variable clinical symptoms and therefore undergo a completely different treatment with different outcomes, we detected such differences in the cases we report, specifically when evaluating immune function. Patient 1 had lymphopenia from birth, with severe T- and B-cell depletion, while patient 2 had lymphocytes within the normal range. Interestingly, patient 1 had a restricted TCR regardless of any underlying infection, which could potentially lead to abnormal T-cell selection or Omenn syndrome. In contrast, patient 2 had a diverse TCR, which was normal compared to a healthy control. The Shannon H diversity index for the repertoires of patient 1 was relatively low, compared with patient 2 and the controls. Similar results were also observed for the Simpson D index. Using advanced methods, such as NGS, we were able to show differences in the immunologic profile between the patients, eventually leading to different clinical outcomes.

Moreover, we observed a genotype-phenotype correlation, which is also supported by the literature [10,13,26,27]. In patient 1, the positions of the 2 known mutations—4 base pairs before the TIS (maternal) and at +238 (paternal)—can explain her severe clinical phenotype of immune deficiency and bone dysplasia. Thiel et al [10] suggested that insertions, duplications, and triplications within the conserved 24- to 26-bp region between the TATA box and TIS, as in the maternal mutation, cause reduced RMRP transcription, which resulted from impaired binding of the RNA polymerase III transcription factor complex, leading to a cellular phenotype of defects in rRNA cleavage and ribosome assembly and a clinical phenotype of bone dysplasia [10]. The other mutation lies within the P4 region of RMRP, which is responsible for the regulation of cell cycle progression at G2 through mRNA cleavage, leading to immune deficiency in the case of a mutation there [10,11]. Patient 2 harbored a novel homozygous regulatory mutation at position +222, which lies in the P1 and P2 regions of RMRP and is responsible for its rRNA cleavage activity and ribosome assembly, but not immune deficiency. A mutation at +220, ie, 2 nucleotides upstream from the mutation we describe, is associated with milder phenotypes [10]. Indeed, the clinical manifestations of milder bone dysplasia and very mild immune deficiency observed in patient 2, compared with patient 1, correlate well with the genetic findings. Although the TCR for patient 2 was diverse, we recorded low TREC levels at the age of 1 year. We cannot assume the TREC results for the newborn period, but we can learn about the high sensitivity of the test in T-cell immunodeficiency. One explanation could be the mild restrictions found in the TCR-Vβ examination.

Therapy in CHH is focused on immunodeficiency. Most of the other available therapies for CHH patients are mainly palliative. HSCT has profoundly changed the natural history of severe T-lymphocyte deficiency, including SCID and other syndromes associated with severe T-cell lymphopenia. Excellent outcomes have been reported for SCID and other moderate T-lymphocyte dysfunctions. After HSCT, patients have been reported to reach the age of 30 [14,28,29]. The current understanding is that not all CHH patients should be considered for HSCT, only those with chronic or recurrent infections and an available matched donor. Profound immunodeficiency associated with CHH can be cured by stem cell transplantation. Unfortunately, replacing hematopoietic stem cells does not seem to improve skeletal dysplasia [23,25]. In our report, patient 1 went through successful HSCT from a matched related donor. It has been 3 years since the procedure, and the patient is alive and well, does not require immunological therapy, and has experienced no significant complications. In contrast, patient 2 was advised to continue regular follow-up and receive symptomatic treatment.

In summary, we describe 2 unrelated CHH patients with distinct clinical presentations and immune work-up findings and different modes of diagnosis. In order to delineate the differences between these patients, which eventually led to
different treatment approaches, we included analyses of their TCR using advanced methodologies. We showed how this could help to choose the appropriate treatment for each patient. Detection of patients through the newborn screening program for severe T-cell immunodeficiency can help in the decision-making process when treating newborns with immunodeficiency, as in the CHH case we report, thus enabling the patient to benefit from early HSCT.

Acknowledgments

The authors thank the patients and their families for their collaboration and are grateful for the expert care provided by the interdisciplinary pediatric teams.

Funding

The authors declare that no funding was received for the present study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References


Manuscript received August 19, 2021; accepted for publication February 9, 2022.

Raz Somech
Pediatric Department and the Immunology Service
"Edmond and Lily Safra" Children’s Hospital
Sheba Medical Center
Tel Hashomer, 52621, Israel
E-mail: raz.somech@sheba.health.gov.il

Amos J Simon
Hematology Laboratory, Hemato-Immunology Unit
and Sheba Cancer Research Center
Sheba Medical Center
Tel Hashomer, 52621, Israel
E-mail: amos.simon@sheba.health.gov.il